SOURCE: Active Biotech

June 12, 2008 03:31 ET

Active Biotech's new issue fully subscribed

LUND, SWEDEN--(Marketwire - June 12, 2008) - Active Biotech's new issue with preferential rights for the company's shareholders has been completed. Nordstjernan AB and MGA Holding AB subscribed for their respective preferential part of the new issue. In addition hereto, Nordstjernan AB, that guaranteed the new issue, subscribed for a further 150,087 shares, corresponding to 3.8 per cent of the shares issued. Accordingly, the new issue was subscribed for in its entirety. Following the new issue, Nordstjernan AB and MGA Holding AB own 15.3 per cent and 30.0 per cent, respectively, of the shares and votes in Active Biotech.


As a consequence of the new issue, the number of shares and votes in the company increases with 3,941,676 to 51,241,791.

The new issue will provide Active Biotech with approximately SEK 157.7 M before deductions for issue expenses.

Last day for trading with interim shares "BTA" is June 18. Trading in the new shares on the OMX Nordic Exchange Stockholm is expected to commence on or about June 25, 2008, or already prior to that depending on when the Swedish Companies Registration Office has registered the new issue.

Lund, June 12, 2008
Active Biotech AB (publ)

Sven Andréasson
President and CEO

For further information, please contact:
Sven Andréasson
Tel: +46 (0)46 19 20 49
E-mail: sven.andreasson@activebiotech.com

Hans Kolam, CFO
Tel: +46 (0) 46 19 20 44
E-mail: hans.kolam@activebiotech.com

About Active Biotech

Active Biotech AB (OMX Nordic: ACTI) is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA.

Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 9:30 a.m. CET on June 12, 2008.

Active Biotech AB
PO Box 724, 220 07 Lund
Sweden
Tel +46 (0)46-19 20 00
Fax +46 (0)46-19 20 50

This press release does not constitute an offer of any securities of Active Biotech. The rights issue is not directed towards shareholders or other investors in the United States of America, Canada, Japan or Australia or other countries where participation would require further prospectuses, registration or other measures than those pursuant to Swedish law. No shares, interim shares, subscription rights or other securities of Active Biotech have been or will be registered under the United States Securities Act of 1933, under the securities laws of any state of the United States or under any province law in Canada. Therefore, no new shares, interim shares, subscription rights or other securities of Active Biotech may be offered or sold, renounced, taken up or delivered in the United States or Canada except pursuant to an exemption from registration.





Copyright © Hugin AS 2008. All rights reserved.

Contact Information